EUVIMEDEUVIMED entdecken
Open Access

Repaglinide restrains HCC development and progression by targeting FOXO3/lumican/p53 axis

Yifei Tan, Yongjie Zhou, Wei Zhang, Zhenru Wu, Qing Xu, Qiong Wu, Jian Yang, Tao Lv, Lvnan Yan, Hong Luo, Yujun Shi, Jiayin Yang

Cellular Oncology · 2024-08 · 47 (4) · 1167-1181

DOI: 10.1007/s13402-024-00919-9 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cellular Oncology, online erschienen am 07.02.2024. Verfasst von Yifei Tan und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Liver Transplantation Center and Laboratory of Liver Transplantation, West China Hospital of Sichuan University, Chengdu, China. Hauptthemen laut MEDLINE: Liver Neoplasms, Carcinoma, Hepatocellular, Forkhead Box Protein O3, Tumor Suppressor Protein p53. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Liver NeoplasmsCarcinoma, HepatocellularForkhead Box Protein O3Tumor Suppressor Protein p53Disease ProgressionSignal TransductionLumicanHumansAnimalsMiceCell Line, TumorMaleGene Expression Regulation, NeoplasticCell ProliferationFemaleMiddle AgedMice, NudeCarbamatesPiperidines

Stichwörter der Autor:innen

FOXO3Hepatocellular carcinomaLumicanRepaglinidep53

Substanzen

Forkhead Box Protein O3Tumor Suppressor Protein p53LumicanrepaglinideFOXO3 protein, humanCarbamatesPiperidines

Autor:innen und Institutionen

  • Department of Liver Transplantation Center and Laboratory of Liver Transplantation, West China Hospital of Sichuan University, Chengdu, China.
  • Department of Ultrasonography, West China Second University Hospital, Sichuan University, Chengdu, China.
  • Breast Tumor Center, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China.
  • Laboratory of Pathology, Key Laboratory of Transplant Engineering and Immunology, NHC, West China Hospital of Sichuan University, Chengdu, 610041, China.
  • Department of Ultrasonography, West China Second University Hospital, Sichuan University, Chengdu, China. luohongcd1969@163.com.
  • Department of Liver Transplantation Center and Laboratory of Liver Transplantation, West China Hospital of Sichuan University, Chengdu, China. shiyujun@scu.edu.cn.

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Tan, Y., Zhou, Y., Zhang, W., Wu, Z., Xu, Q., Wu, Q., Yang, J., Lv, T., Yan, L., Luo, H., Shi, Y., & Yang, J. (2024). Repaglinide restrains HCC development and progression by targeting FOXO3/lumican/p53 axis. Cellular Oncology, 47(4), 1167-1181. https://doi.org/10.1007/s13402-024-00919-9

Vancouver

Tan Y, Zhou Y, Zhang W, Wu Z, Xu Q, Wu Q, et al. Repaglinide restrains HCC development and progression by targeting FOXO3/lumican/p53 axis. Cellular Oncology. 2024;47(4):1167-1181. doi:10.1007/s13402-024-00919-9

BibTeX
@article{Tan2024,
  author = {Tan, Yifei and Zhou, Yongjie and Zhang, Wei and Wu, Zhenru and Xu, Qing and Wu, Qiong and Yang, Jian and Lv, Tao and Yan, Lvnan and Luo, Hong and Shi, Yujun and Yang, Jiayin},
  title = {Repaglinide restrains HCC development and progression by targeting FOXO3/lumican/p53 axis},
  journal = {Cellular Oncology},
  year = {2024},
  volume = {47},
  number = {4},
  pages = {1167--1181},
  doi = {10.1007/s13402-024-00919-9}
}
Kostenlos starten →